STOCK TITAN

Annexon Inc - ANNX STOCK NEWS

Welcome to our dedicated news page for Annexon (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Annexon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Annexon's position in the market.

Rhea-AI Summary
Annexon, Inc. grants inducement awards to two new non-executive employees under Nasdaq Listing Rule 5635(c)(4), offering options to purchase 27,480 shares of common stock at $5.74 per share, vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) will have its president and CEO, Douglas Love, participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. The company is focused on developing novel therapies for complement-mediated neuroinflammatory diseases. The event will be webcast live and available for replay on the Annexon website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
-
Rhea-AI Summary
Annexon, Inc. (ANNX) announces pivotal Phase 3 data for ANX005 in Guillain-Barré Syndrome (GBS) expected in Q2 2024, initiation of Phase 3 ANX007 ARCHER II trial in Geographic Atrophy (GA) in mid-2024, and clinical proof-of-concept data with ANX1502 oral inhibitor of the Classical Pathway in the second half of 2024. The company reported a robust balance sheet with approximately $260 million in cash, cash equivalents, and short-term investments as of December 31, 2023, ensuring runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.52%
Tags
Rhea-AI Summary
Annexon, Inc. grants an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan. The employee receives an option to purchase 3,500 shares of Annexon common stock at an exercise price of $6.69 per share, with vesting over 4 years. The award was approved on March 15, 2024, in line with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary
Annexon, Inc. (ANNX) will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. The event will focus on Ophthalmology, showcasing the company's complement-based medicines for inflammatory diseases. Douglas Love, the CEO, will represent Annexon in Boston, MA, on March 5, 2024, at 12:10 p.m. ET. Investors can access the live webcast on the company's website and view the replay for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX) will host a virtual R&D Day featuring GBS experts to discuss Guillain-Barré syndrome and their investigational monoclonal antibody ANX005. The event will highlight the current treatment landscape, Annexon's Phase 3 trial, and the commercial approach to the GBS market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
conferences
Rhea-AI Summary
Annexon, Inc. granted an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan. The employee received an option to purchase 10,800 shares of Annexon common stock at an exercise price of $5.13 per share, vesting over 4 years. The award was approved on February 16, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
none
-
Rhea-AI Summary
Annexon, Inc. (ANX) outlines strategic priorities for 2024, including late-stage clinical milestones for ANX005 in Guillain-Barré Syndrome, ANX007 in Geographic Atrophy, and ANX1502 for autoimmune indications. The company has reported successful $125 million financing, extending its operating runway into the second quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
-
Rhea-AI Summary
Annexon, Inc. (ANNX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
conferences
Rhea-AI Summary
Annexon, Inc. (NASDAQ: ANNX) announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The total gross proceeds are expected to be approximately $125.0 million. The offering is expected to close on December 26, 2023. Jefferies and TD Cowen are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
Annexon Inc

Nasdaq:ANNX

ANNX Rankings

ANNX Stock Data

460.48M
49.27M
8.68%
95.4%
3.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Brisbane

About ANNX

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).